3:15 PM - 3:30 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
AULBIO is a research-intensive biotechnology company located in Korea. It is engaged globally in the research/development and commercialization of highly technical and innovatively formulated brand products based on cutting-edge drug delivery technology (DDT).

Using its proprietary platform technology (Extenna Microsphere Drug Delivery Technology), it is developing long-acting bio-pharmaceutical products that are designed to reduce the number of dosing frequency significantly, resulting in improving the well-being of patients.

We want to position ourselves enthusiastically and optimistically as a leading innovator in the global biopharmaceutical market, today and for the future.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
February 01, 2018
Main Therapeutic Focus:
Lead Product in Development:
Tirzepatide monthly inj., Semaglutide monthly inj.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):